Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia

Technology appraisal guidance
Reference number: TA218
Published: 23 March 2011

Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation

Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation

Myelodysplastic syndromes - azacitidine: response to consultee, commentator and public comments on the ACD and comments from website consultation
17 February 2011
(88.94 Kb 25 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 16 February 2011